Hathal Haddad, Head of Interventional Radiotherapy Unit at University Hospital Tübingen, shared a post on LinkedIn:
“19 Days Until Brachytherapy Awareness Day 2026
Interventional Radiotherapy for Treating Skin Cancers
Skin cancer is the most common cancer worldwide, and its incidence continues to rise.
For patients with Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), Interventional Radiotherapy (Brachytherapy) offers a highly effective, organ-preserving treatment with excellent cosmetic outcomes.
Following the recommendations of the GEC-ESTRO Skin Brachytherapy Working Group, modern HDR brachytherapy enables highly conformal dose delivery while minimizing radiation exposure to surrounding healthy tissues.
Why choose brachytherapy for skin cancers?
- Excellent local control
- Maximum preservation of healthy skin
- Outstanding cosmetic outcomes
- Treatment completed in only a few sessions
- Outpatient treatment for many patients
- Ideal for lesions in cosmetically and functionally sensitive areas such as the nose, ear, eyelid, lip, and scalp.
By delivering radiation directly to the tumor, brachytherapy achieves a steep dose fall-off, allowing high tumor doses while protecting adjacent critical structures. This is precision medicine in its purest form.
Treat the tumor. Preserve the patient.
Better Care. Better Outcomes. Better Quality of Life.
17 July 2026 – Brachytherapy Awareness Day.”
Other articles about radiotherapy on OncoDaily.